Treatment Progress of SGLT2 Inhibitors in Anemia of CKD

贫血是CKD患者的重要并发症，传统治疗依赖EPO、铁剂、HIF-PHI，但存在疗效局限性及副作用。SGLT2is因其肾脏保护作用备受关注，近年研究发现其对CKD贫血具有潜在改善作用，本文综述SGLT2is改善贫血的机制、临床证据及未来研究方向。Anemia is an important complication in patients with CKD, traditional treatment relies on EPO, iron and HIF-PHI, but has limited efficacy and side effects. SGLT2is has attracted much attention due to its renal protective effect. Recent studies have found that SGLT2is has a potential effect on improving anemia in CKD. This article reviews the mechanism, clinical evidence, and future research directions of SGLT2is in improving anemia.